June 30, 2026 · Form 4 insider transaction
Pershing Edward bought 45,860 shares of Provectus Biopharmaceuticals, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.
Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").; The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.; The amount reported reflects an adjustment to correct a typographical error in a previously filed Form 4. This adjustment does not reflect a transaction by the Reporting Person.